The US Food and Drug Administration has granted approval for the inaugural gene therapy aimed at addressing genetic hearing impairment—a groundbreaking achievement that has the potential to restore hearing for numerous Americans who are born with hereditary deafness. This therapy targets mutations in the genes that affect the auditory hair cells in the inner ear, which can lead to significant to profound hearing loss from birth if damaged or missing. The FDA's endorsement signifies a pivotal shift in treatment possibilities that have historically depended solely on hearing aids and cochlear implants. Researchers believe this gene therapy method could enable near-normal hearing for qualifying patients, especially if children receive treatment at an early age.
